Author

S. D. Fortmann

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 1 Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 3 Research Focus:differential expression· 2 Approach:experimental assay· 2 Organism:mouse· 2 Assay:scRNA-seq· 2 Research Focus:cell signaling & trafficking· 1 Assay:CITE-seq· 1 Organism:human· 1

Frequent Co-Authors

M. B. Grant· 3 shared C. P. Vieira· 2 shared J. L. Floyd· 2 shared M. DuPont· 2 shared R. S. Welner· 2 shared A. Goldsborough· 1 shared A. Harbour· 1 shared A. L. Longhini· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

M. B. Grant

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Fixation Before Dissociation Using a Deep Eutectic Solvent Preserves In Vivo States and Phospho-Signaling in Single-Cell Sequencing

S. D. Fortmann, B. F. Frey, V. S. Hanumanthu, S. Liu, A. Goldsborough, K. V. Kilchrist, P. B. Ferrell, C. T. Weaver, M. B. Grant, R. S. Welner

This study introduces a deep eutectic solvent fixation method that preserves in vivo cellular states and phospho-signaling for scRNA-seq, enabling the identification of hyperactivated Th17 T cells.

bioRxiv · Feb 13, 2023 · PreprintImmunology

Plasma microbiome in COVID-19 subjects: an indicator of gut barrier defects and dysbiosis

R. Prasad, M. J. Patton, J. L. Floyd, C. P. Vieira, S. D. Fortmann, M. DuPont, A. Harbour, J. R. Chen See, J. Wright, R. Lamendella, B. R. Stevens, M. B. Grant

The paper analyzes plasma microbiome and permeability markers in COVID-19 patients and healthy controls, finding higher gut permeability and gram-negative bacteria abundance in patients.

bioRxiv · Apr 6, 2021 · PreprintMicrobiology

Selective LXR agonist, DMHCA, corrects the retina-bone marrow axis in type 2 diabetes

C. P. Vieira, S. D. Fortmann, M. Hossain, A. L. Longhini, S. S. Hammer, B. Asare-Bediako, D. K. Crossman, M. S. Sielski, Y. Adu-Agyeiwaah, M. Dupont, J. L. Floyd, S. Li Calzi, T. Lydic, R. S. Welner, G. J. Blanchard, , M. B. Grant

This study shows that DMHCA, a selective LXR agonist, corrects the retina-bone marrow axis in type 2 diabetes by restoring retinal function, cholesterol homeostasis, and hematopoietic stem cell balance.

bioRxiv · Feb 11, 2020 · PreprintCell Biology